155 related articles for article (PubMed ID: 37211774)
1. The future is here-targeted therapies are coming of age in biliary tract cancers.
Neureiter D; Ocker M
Chin Clin Oncol; 2023 Jun; 12(3):20. PubMed ID: 37211774
[No Abstract] [Full Text] [Related]
2. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
[TBL] [Abstract][Full Text] [Related]
3. What are the key challenges in the pharmacological management of cholangiocarcinoma?
Ledenko M; Patel T
Expert Opin Pharmacother; 2022 Apr; 23(5):531-533. PubMed ID: 34866539
[No Abstract] [Full Text] [Related]
4. Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
Ricci AD; Rizzo A
Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946246
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
Mayr C; Kiesslich T; Modest DP; Stintzing S; Ocker M; Neureiter D
Expert Opin Investig Drugs; 2022 Feb; 31(2):221-233. PubMed ID: 35098846
[TBL] [Abstract][Full Text] [Related]
7. Advances in immunotherapy for biliary tract cancers.
Zhao Y; Yang M; Feng J; Wang X; Liu Y
Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
[TBL] [Abstract][Full Text] [Related]
8. FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions.
Neureiter D; Ellinghaus P; Ocker M
Expert Opin Pharmacother; 2023; 24(17):1833-1837. PubMed ID: 37710362
[No Abstract] [Full Text] [Related]
9. The state of therapy modalities in clinic for biliary tract cancer.
Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
11. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
Merters J; Lamarca A
J Hepatol; 2023 Mar; 78(3):652-657. PubMed ID: 36400328
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for biliary tract cancers.
Faris JE; Zhu AX
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):326-36. PubMed ID: 22318523
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Biliary Tract Cancers: Where Are We?
Kalyan A; Khosla H; Kim RD
Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.
Kim H; Kim JY; Park KU
Oncology; 2023; 101(1):41-48. PubMed ID: 36257294
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Valéry M; Cervantes B; Smolenschi C; Boige V; Ducreux M; Cohen R; Hollebecque A
Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759
[TBL] [Abstract][Full Text] [Related]
16. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
[TBL] [Abstract][Full Text] [Related]
17. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics and targeted therapeutics in biliary tract carcinoma.
Marks EI; Yee NS
World J Gastroenterol; 2016 Jan; 22(4):1335-47. PubMed ID: 26819503
[TBL] [Abstract][Full Text] [Related]
19. Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
[No Abstract] [Full Text] [Related]
20. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]